Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mallinckrodt PLC MNKTQ

Healthcare
Mallinckrodt plc develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and... see more

Recent & Breaking News (OTCPK:MNKTQ)

Mallinckrodt Shareholder Notice

Newsfile July 12, 2023

Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

Business Wire July 12, 2023

Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

PR Newswire July 11, 2023

Mallinckrodt Deadline Alert

Newsfile July 11, 2023

ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Mallinckrodt plc Investors with losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - MNK, MNKPF

Newsfile July 11, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Mallinckrodt Plc and Certain Officers - MNK

Newsfile July 7, 2023

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) Congress 2023

PR Newswire June 15, 2023

Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023

PR Newswire June 1, 2023

Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

PR Newswire May 9, 2023

Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023

PR Newswire May 8, 2023

Mallinckrodt Recognized as Industry Innovator at National Organization for Rare Disorders (NORD) 2023 Rare Impact Awards

PR Newswire May 5, 2023

Buxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding Failure to Address Evidential Multibillion-Dollar Asset Value Depreciation Expense Concealment Scheme

Business Wire April 28, 2023

Mallinckrodt to Report Earnings Results for First Quarter 2023

PR Newswire April 24, 2023

ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK

PR Newswire April 16, 2023

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK

Newsfile April 15, 2023

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK

PR Newswire April 13, 2023

MNK Equity Notice: ROSEN, Global Investor Counsel, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK

Newsfile April 10, 2023

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the National Kidney Foundation (NKF) 2023 Spring Clinical Meeting (SCM)

PR Newswire April 10, 2023

ROSEN, LEADING INVESTOR COUNSEL, Encourages Mallinckrodt plc Investors to Inquire About Securities Class Action Investigation - MNK

PR Newswire April 7, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mallinckrodt plc - MNK

PR Newswire April 3, 2023